Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.49 |
| ▸ | MMP12 | P39900 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8623391 | 1.00 | LTA4H (0.56) | LTA4HEPHX2FFAR1HDAC2TDP1 | |
| SCHEMBL2162241 | 0.93 | HDAC2 (0.56) | LTA4HEPHX2FFAR1HDAC2TDP1 | |
| Biphenyl SCHEMBL27528312 | 0.93 | TDP1 (0.61) | LTA4HEPHX2FFAR1HDAC2TDP1 | |
| SCHEMBL5534575 | 0.91 | HDAC2 (0.57) | LTA4HEPHX2FFAR1HDAC2TDP1 | |
| SCHEMBL5540196 | 0.91 | HDAC2 (0.57) | LTA4HEPHX2FFAR1HDAC2TDP1 | |
| SCHEMBL3535251 | 0.91 | CA2 (0.54) | LTA4HEPHX2FFAR1TDP1CA2 | |
| SCHEMBL10001880 | 0.89 | MEN1 (0.53) | LTA4HEPHX2FFAR1HDAC2TDP1 | |
| SCHEMBL19730229 | 0.87 | MEN1 (0.46) | LTA4HEPHX2FFAR1HDAC2HDAC1 | |
| SCHEMBL22251662 | 0.86 | TDP1 (0.71) | FFAR1HDAC2TDP1MMP12ABCC4 | |
| SCHEMBL1938644 | 0.86 | TDP1 (0.71) | FFAR1HDAC2TDP1MMP12ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5043312-A | Mixture of imino and isocyanate compounds, biphenyl alcohol in binder on support; image preservation, heat responsiveness | MITSUBISHI PAPER MILLS LIMITED (JP) | 1991-08-27 | — | — | US | claimed |
| WO-2023206874-A1 | SACUBITRIL INTERMEDIATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 凯特立斯（深圳）科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| EP-3558930-B1 | NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES | NOVARTIS AG (CH) | 2021-05-26 | — | — | EP | disclosed |
| US-10829464-B2 | Benzoheterocyclic alkylamine compounds and use thereof | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2020-11-10 | — | — | US | disclosed |
| US-20190315703-A1 | BENZOHETEROCYCLIC ALKYLAMINE COMPOUNDS AND USE THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2019-10-17 | — | — | US | disclosed |
| WO-2018095287-A1 | BENZOHETEROCYCLYL ALKYLAMINE COMPOUND AND USE THEREOF | 华东理工大学 | 2018-05-31 | — | — | WO | disclosed |
| EP-2890672-B1 | PROCESSES FOR PREPARING INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2018-05-30 | — | — | EP | disclosed |
| EP-2837642-B1 | PHOTOCURABLE COMPOSITION AND ENCAPSULATED APPARATUS PREPARED USING THE SAME | SAMSUNG SDI CO LTD (KR) | 2018-05-09 | — | — | EP | disclosed |
| CN-105142673-B | Novel cyclohexyl and quininuclidinyl carbamate derivatives with beta 2-adrenergic activator and M3 muscarinic antagonists activity | 阿尔米雷尔有限公司 | 2018-01-05 | — | — | CN | disclosed |
| US-9809537-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-5741438-A | Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as an effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-04-21 | — | — | US | disclosed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0395390-B1 | Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL CO (JP) | 1994-09-28 | — | — | EP | disclosed |
| US-5043312-A | Mixture of imino and isocyanate compounds, biphenyl alcohol in binder on support; image preservation, heat responsiveness | MITSUBISHI PAPER MILLS LIMITED (JP) | 1991-08-27 | — | — | US | disclosed |
| EP-0395390-A1 | Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-10-31 | — | — | EP | disclosed |
| US-4613597-A | ANTICOAGULANTS, VASODILATORS, BRONCHODILATORS | GLAXO GROUP LIMITED (GB) | 1986-09-23 | — | — | US | disclosed |
| US-4342756-A | AS ANTITHROMBOTIC AGENTS AND ANTIASTHMATIC AGENTS | GLAXO GROUP LIMITED (GB) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829464-B2 | Benzoheterocyclic alkylamine compounds and use thereof | AADAC, AAAS, NISCH | LTA4H 123/4885EPHX2 1823/4885FFAR1 3546/4885 |
| US-20190315703-A1 | BENZOHETEROCYCLIC ALKYLAMINE COMPOUNDS AND USE THEREOF | AADAC, AAAS, NISCH | LTA4H 123/4885EPHX2 1823/4885FFAR1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.